KaydedilenlerDerginizi ekleyin

Dergiler / Osmangazi Tıp Dergisi / 2026 / Cilt: 44 Sayı: 4

Multipl Skleroz Olarak Yanlış Teşhis Edilen Antifosfolipid Sendromu: Bir Olgu Sunumu.

Anti-Phosholipid Syndrome Misdiagnosed As Multiple Sclerosis: A Case Report.

Gülnur Tekgöl Uzuner(ESKİŞEHİR OSMANGAZİ ÜNİVERSİTESİ)0000-0002-9795-4817
Atilla Özcan Özdemir(ESKİŞEHİR OSMANGAZİ ÜNİVERSİTESİ, TIP FAKÜLTESİ, TIP PR.)0000-0002-9864-6904
Cengiz Korkmaz(ESKİŞEHİR OSMANGAZİ ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI)0000-0003-2679-0699
Nevzat Uzuner(ESKISEHIR OSMANGAZI UNIVERSITY, SCHOOL OF MEDICINE)0000-0002-4961-4332
Sayfa
580–586
Yayın Tarihi
2022-07-19
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

MS hastalarını değerlendirirken, klinisyenler MS'nin atipik özellikleri varsa AFAS’ı düşünmelidir.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Multipl skleroz ve anti-fosfolipid sendromu (AFAS), genç yetişkinleri etkileyen kronik, immün aracılı, relapsing-remitting bozukluklardır.
📊
Temel Bulgular & Veri:Ayrıca farklı zamanlarda akut miyokard infarktüsü ve iskemik inme geçirmişti.
💡
Sonuç & Katkı:MS hastalarını değerlendirirken, klinisyenler MS'nin atipik özellikleri varsa AFAS’ı düşünmelidir.
🔬Tür:Olgu Sunumu
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Multiple Skleroz · Anti-fosfolipid sendrom · Yanlış tanı

Özet

Multipl skleroz ve anti-fosfolipid sendromu (AFAS), genç yetişkinleri etkileyen kronik, immün aracılı, relapsing-remitting bozukluklardır. AFAS, anti-fosfolipid antikorları ile ilişkili tromboz ve gebelik mortalitesi ile karakterizedir. AFAS tanısı zor olabilir ve AFAS’lı hastaların yanlış multipl skleroz tanısı alması nadir değildir. Bu olgu sunumunda, on bir yıldır multipl skleroz tanısı ile izlenen bir hastayı tanımladık. Başlangıçta hastanın MS benzeri relapsing- remitting seyirli nörolojik defisitleri vardı ancak MS'in klasik manyetik rezonans görüntüleme görünümü ve beyin omurilik sıvısında oligoklonal bantlar yoktu. Hasta MS tanı kriterlerinde belirtilen ‘zamanda ve mekanda yayılım kriterleri’ ni karşılamıyordu. Ayrıca farklı zamanlarda akut miyokard infarktüsü ve iskemik inme geçirmişti. Primer AFAS tanısı, hastanın iskemik serebral inme geçirmesi, nöbet ve iki kez aPL pozitif olması üzerine konuldu. Gözlemlerimiz, AFAS’ın erken ve doğru teşhisinin önemi konusunda farkındalık yaratmaktadır. MS hastalarını değerlendirirken, klinisyenler MS'nin atipik özellikleri varsa AFAS’ı düşünmelidir.

Abstract

Multiple sclerosis (MS) and anti-phospholipid syndrome (APS) are chronic, immune-mediated, relapsing-remitting disorders affecting young adults. APS is characterized by thrombosis and pregnancy mortality associated with anti-phospholipid antibodies. The diagnosis of APS may be difficult, and it is not uncommon for patients with APS to be misdiagnosed with multiple sclerosis. In this case report, we describe a patient who was diagnosed as having multiple sclerosis for eleven-year. Initially, the patient had neurological deficits with relapsing-remitting courses, like MS but he had not classic magnetic resonance imaging appearance of MS and absence of oligoclonal bands in the cerebrospinal fluid. He did not meet the 'dissemination criteria in time and place' specified in the MS diagnostic criteria. Also, he had an acute myocardial infarction and ischemic stroke at different times. The diagnosis of primary APS was made after the patient had thrombotic attacks, seizure and was positive for anti-phospholipid antibodies (aPLs) twice. Our observations raise awareness about the importance of the early and correct diagnosis of APS. When assessing MS patients, clinicians should consider APS, if the MS has atypical features.

🔖

Bu Makaleye Atıf Yap

Uzuner, G. T., Özdemir, A. Ö., Korkmaz, C., Uzuner, N. (2022). Multipl Skleroz Olarak Yanlış Teşhis Edilen Antifosfolipid Sendromu: Bir Olgu Sunumu.. Osmangazi Tıp Dergisi, Cilt: 44 Sayı: 4, 580–586. https://doi.org/10.20515/otd.978880

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (26)

  1. Referans 1 Myakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
  2. Referans 2. Laura Durcan and Michelle Petri. Epidemiology of the Antiphospholipid Syndrome Chapter 2. Handbook of Systemic Autoimmune Diseases. 2017;12:17-30.
  3. Referans 3. Yoav Arnson, Yehuda Shoenfeld, Eisen Alon and Howard Amita. Antiphosholipid syndrome as neurological disease. Semin Arthritis Rheum. 2010; 40:97-108.
  4. Referans 4. Andrew J, Solomon, Brain G. Weinshenker. Misdiagnosis of multiple sclerosis: Frequency, Causes, Effects, and Prevention. Curr. Neurol neurosci Rep. 2013; 13:403.
  5. Referans 5. Cervera R, Piette JC, Front J, et al. Antiphospkolipid syndrome:clinical and immunologic manifestations and patterns of disease expression in a cohort of 1.000 patients. Arthritis rheum. 2002;46:1019-27.
  6. Referans 6. Sanna G, Bertolaccini ML, Cuadrado MJ, et al. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology. 2003;42:200-13.
  7. Referans 7. Lockshin M, Tenedios F, Petri M, et al. Cardiac disease in the antiphospholipid syndrome:recommendations for treatment. Committee consensus report. Lupus. 2003;12:518-23.
  8. Referans 8. Guillermo RI, Crowther M, Branch W, et al. Anti-phospholipid syndrome. Lancet. 2010;376:1498-1509.
  9. Referans 9. Hughes GR. Thrombosis,abortion,cerebral disease,and the lupus anticoagulant. Br Med J (Clin Res Ed). 1983; 287(6399): 1088–1089.
  10. Referans 10. Sanna G, D’Cruz D,Cuadrado MJ. Cerebral manifestations in the antiphospholipid (Hughes) syndrome. Rheum Dis Clin North Am. 2006; 32(3): 465–490.
  11. Referans 11. Yelnik CM, Kozora E, Appenzeller S. Non-stroke central neurologic manifestations in antiphospholipid syndrome. Curr Rheumatol Rep. 2016; 18(2): 11.
  12. Referans 12. Rodrigues CEM, Carvalho JF, Shoenfeld Y. Neurological manifestations of anti- phospholipid syndrome. Eur J Clin Invest. 2010; 40(4): 350–359.
  13. Referans 13. Gris JC, Nobile B, Bouvier S. Neuropsychiatric presentations of antiphospholipid antibodies. Thromb Res. 2015; 135 (Suppl 1): S56–S59.
  14. Referans 14. Fernandez-Fernandez FJ,Rivera-Gallego A,de la Fuente-Aguado J, et al. Antiphospholipid syndrome mimicking multiple sclerosis in two patients. Eur J Intern Med. 2006; 17(7): 500–502.
  15. Referans 15. Cuadrado MJ, Khamashta MA, Ballesteros A, et al. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore). 2000; 79(1): 57–68.
  16. Referans 16. Zhu, D.-.S., Fu, J., Zhang, Y, et al. Neurological antiphospholipid syndrome: clinical, neuroimaging, and pathological characteristics. J. Neurol. Sci. 2014; 346 (1–2), 138–144.
  17. Referans 17. Keiserman B, da Silva LF, Keiserman MW, et al. Lupoid sclerosis. Rheumatol Int. 2010;30:431–4.
  18. Referans 18. Heinzlef O, Weill B, Johanet C, et al. Anticardiolipin antibodies in patients with multiple sclerosis do not represent a subgroup of patients according to clinical, familial, and biological characteristics. J Neurol Neurosurg Psychiatry. 2002; 72(5): 647–649.
  19. Referans 19. Liedorp M, Sanchez E, van Hoogstraten IMW, et al. No evidence of misdiagnosis in patients with multiple sclerosis and repeated positive anticardio- lipin antibody testing based on magnetic resonance imaging and long term follow-up. J Neurol Neurosurg Psychiatry. 2007; 78(10): 1146–1148.
  20. Referans 20. Bidot CJ, Horstman LL, Jy W, et al. Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: A preliminary study. BMC Neurol. 2007; 7: 36.
  21. Referans 21. Szmyrka-Kaczmarek M, Pokryszko-Dragan A, Pawlik B, et al. Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis. Lupus. 2012; 21: 412–420.
  22. Referans 22. Karussis D, Leker RR, Ashkenazi A, et al. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: Do they represent a new nosological entity? Ann Neurol. 1998; 44: 629–634.
  23. Referans 23. Baraczka K, Lakos G, Sipka S. Immunoserological changes in the cerebro-spinal fluid and serum in systemic lupus erythematosus patients with demyelinating syndrome and multiple sclerosis. Acta Neurol Scand. 2002; 105: 378–383.
  24. Referans 24. Roussel V, Yi F, Jauberteau MO, et al. Prevalence and clinical significance of anti-phospholipid antibodies in multiple sclerosis: A study of 89 patients. J Autoimmun. 2000; 14: 259–265.
  25. Referans 25. Garg N, Zivadinov R, Ramanathan M, et al. Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. J Neuroimmunol. 2007; 187: 159–165.
  26. Referans 26. Maria J Cuadrado, Munther A. Khamashta, Angel Ballesteros, et al. Can Neurologic manifestations of Hughes (Antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literatüre. Medicine. 2000;Vol (79) No.1:57-68.